In this prospective cohort study of 161 nulligravid women, there was no reliable threshold of uterine length or flexion angle measurements that were predictive of painful or difficult insertions. History of severe dysmenorrhea was the only predictor of insertion pain.
Barriers to guideline-adherent care for advanced ovarian cancer are impacted by geographic proximity to a high-volume hospital and travel distance. However, these geographic barriers disproportionately affect racial minorities and women of lower socioeconomic status.
Prolapse occurs along a spectrum from early and asymptomatic to advanced and symptomatic. The authors define anatomic cutoffs that are likely to result in symptomatic and clinically significant prolapse.
The authors enrolled women desiring postpartum use of a levonorgestrel-releasing intrauterine system in a randomized trial to determine whether use of the device would be higher when insertion occurred immediately postpartum rather than delaying placement to the standard postpartum visit.
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
The rate of sepsis with group b streptococcus (gbs) in neonates of colonized mothers is now less than 1%.
The authors randomized women with objectively validated heavy menstrual bleeding (mean menstrual blood loss [MBL] of 80 mL or more per cycle, confirmed using the alkaline hematin methodology during two pretreatment cycles) to treatment with oral tranexamic acid 3.9 g/d or placebo for up to 5 days per cycle for 6 menstrual cycles.
Nearly every reference source discussing the primary management of advanced ovarian cancer will highlight the role of surgical cytoreduction as an important first step in the care of this disease.
This trial was a randomized double-blind control trial of 89 women undergoing consecutive removal and replacement of a levonorgestrel-releasing intrauterine device (LNG-IUD). Of note, this study was part of a larger multicenter trial evaluating the bleeding profile and safety with repeat use of a LNG-IUD in women who had used their first device for close to 5 years.
